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Abstract
Purpose Lipegfilgrastim, a glycoPEGylated recombinant
granulocyte colony-stimulating factor (G-CSF), reduces neu-
tropenia duration and febrile neutropenia (FN) incidence in
patients with cancer receiving myelosuppressive chemothera-
py. A phase 3 trial of lipegfilgrastim was conducted in patients
with advanced non-small cell lung cancer (NSCLC) receiving
cisplatin/etoposide (which produces mild-to-moderate
myelosuppression). Because patients aged >65 years are at
higher risk for FN versus younger patients, this post hoc anal-
ysis compared outcomes in elderly (>65 years) versus younger
participants in this trial.
Methods Patients were randomized 2:1 to receive a once-per-
cycle single subcutaneous injection of lipegfilgrastim 6 mg or
placebo, with up to 4 cycles of every-3-week cisplatin (day 1)
and etoposide (days 1–3). The primary end point was FN
incidence during cycle 1. Outcomes were compared across
treatment groups and by age groups (≤65 and >65 years).
Results For patients aged ≤65 years, FN incidence during cy-
cle 1 was similar in the lipegfilgrastim and placebo groups
(3.0 vs 3.2 %, respectively), whereas for elderly patients, there
was a reduction in FN incidence with lipegfilgrastim (0 vs
13.3 %, respectively). In both age subgroups, lipegfilgrastim
showed a propensity to reduce the incidence and duration of
severe neutropenia, time to absolute neutrophil count (ANC)
recovery, and depth of ANC nadir. Adverse events were gen-
erally similar between groups.
Conclusions This analysis suggests that in patients with a
higher FN risk, such as the elderly patients of this study,
lipegfilgrastim reduces not only the duration of severe neutro-
penia but also the incidence of FN.
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Background
An estimated 60 % of all malignancies occur in patients
>65 years of age, and the number of elderly patients with
cancer will increase as life expectancy increases and the pop-
ulation ages [1, 2]. In the USA, a 67 % increase in the inci-
dence of all cancers is anticipated for older adults (≥65 years
of age), and the percentage of all cancers diagnosed in elderly
adults is expected to increase from 61 to 70 % by the year
2030 [3].
Without prophylactic therapy, patients receiving myelosup-
pressive chemotherapy for cancer may develop neutropenia or
febrile neutropenia (FN), defined as an absolute neutrophil
count (ANC) of <0.5 × 109/L (grade 4 neutropenia) with fever,
generally defined as an oral body temperature ≥38.3 or
≥38.0 °C for at least 1 h at the same time as the low ANC
level [4, 5]. Neutropenia presents an increased risk of serious
or life-threatening infections and is a major dose-limiting
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toxicity for many chemotherapy regimens [4]. Patients aged
>65 years are likely to have more comorbidities and take more
medications than younger patients, placing them at greater
risk than younger patients for developing myelosuppression
and neutropenia, the duration of which may reduce survival
[1]. Elderly patients are also at increased risk for infections in
the presence or absence of neutropenia [2].
Recombinant granulocyte colony-stimulating factors (G-
CSFs) promote the proliferation and differentiation of neutro-
phils in patients receiving myelosuppressive chemotherapy
who are at risk for FN. G-CSFs are recommended in treatment
guidelines as prophylaxis for reducing the duration of severe
neutropenia (DSN) in patients at a ≥20 % risk of developing
FN [4–6]. G-CSFs have been shown to reduce toxicities asso-
ciated with myelosuppressive chemotherapy, including FN, in
older patients [7, 8]. Lipegfilgrastim, a glycoPEGylated G-
CSF, is approved by the European Medicines Agency for re-
ducing the duration of neutropenia and the incidence of FN in
adults treated with cytotoxic chemotherapy for malignancy
(with the exception of chronic myeloid leukemia and
myelodysplastic syndromes) [9]. The safety and efficacy of
lipegfilgrastim have been demonstrated in clinical trials in
patients with breast cancer [10, 11] and non-small cell lung
cancer (NSCLC) [12]. In a phase 3 trial in patients with
NSCLC, there was no significant difference in the primary
end point of FN incidence between lipegfilgrastim and place-
bo during cycle 1 (2.4 % for lipegfilgrastim vs 5.6 % for
placebo; p = 0.1151); however, significant benefits with
lipegfilgrastim were seen with respect to severe neutropenia,
including a lower incidence (41.4 vs 80.0 %, respectively;
p < 0.0001) and reduced duration (mean 0.6 vs 2.3 days, re-
spectively; p < 0.0001) [12]. To provide an experimental set-
ting that would allow for a placebo control arm from an ethical
standpoint, all patients in this trial received cisplatin plus
etoposide, an effective combination chemotherapy regimen
for NSCLC known to produce only mild to moderate
myelotoxicity, and not necessarily requiring primary G-CSF
prophylaxis according to best practice guidelines [12].
The objective of the following post hoc analysis was to
evaluate the efficacy and safety of lipegfilgrastim in an elderly
subgroup from this phase 3 trial by stratifying patients accord-
ing to age (≤65 and >65 years) [12].
Methods
This was an age-based, post hoc, subgroup analysis of patients
who had participated in a phase 3 multicenter, multinational,
double-blind, randomized, and placebo-controlled trial
(controlled-trials.com identifier ISRCTN55761467). Full
details of the study design and the primary results have been
reported elsewhere [12]. In brief, eligible patients were adults
(aged ≥18 years) who were scheduled to receive 4 cycles of
cisplatin/etoposide as first-line therapy for stage IIIb/IV
NSCLC and had an Eastern Cooperative Oncology Group per-
formance status ≤2, ANC of ≥1.5 × 109/L, platelet count ≥100
× 109/L, and adequate hepatic, renal, and cardiac function.
Patients with an individual high risk of FN according to the
assessment of the investigator (with consideration of risk factors
such as age >65 years, low performance status, poor nutritional
status, and liver, renal, or cardiovascular disease) were to be
excluded from this placebo-controlled study because of ethical
considerations.Within 6months prior to randomization, patients
must have had no exposure to G-CSF products (including
filgrastim, pegfilgrastim, lenograstim, or investigational agents).
Patients were randomized 2:1 to receive a once-per-cycle
single subcutaneous fixed dose injection of lipegfilgrastim
6 mg or placebo [12]. Patients received intravenous (IV) cis-
platin 80 mg/m2 (over at least 1 h) on day 1 and IVetoposide
120 mg/m2 (over at least 1 h) on days 1 to 3 every 3 weeks, for
a maximum of 4 cycles. Study medication was injected sub-
cutaneously on day 4 of each chemotherapy cycle (approxi-
mately 24 h after the last chemotherapy infusion).
Prior to each subsequent cycle, patients were required to
have an ANC of ≥1.5 × 109/L and a platelet count of
≥100 × 109/L, or the next cycle was to be postponed. Dose
delays of up to 2 weeks were allowed, after which time pa-
tients were required to withdraw from the study [12]. Patients
experiencing FN were to receive prophylactic open-label
treatment with lipegfilgrastim during further chemotherapy
cycles (irrespective of double-blind assignment) and were
not to be withdrawn from the study unless deemed necessary
by the investigator. Other G-CSF products were not allowed
during study participation, and the randomized treatment was
not to be unblinded in these patients with documented FN.
Safety was evaluated via assessment for adverse events
(AEs) until 3 weeks after the last dose of study medication.
Blood samples for hematology and clinical chemistry testing
were obtained on day 15 of each cycle.
The primary efficacy end point was the incidence of FN in
cycle 1 of cisplatin/etoposide chemotherapy; FN was defined
as ANC <0.5 × 109/L with oral body temperature of >38.5 °C
on ≥2 consecutive measurements ≥60min apart, or neutropenic
sepsis, or serious or life-threatening neutropenic infection [12].
Severe neutropenia was defined as grade 4 neutropenia with
ANC <0.5 × 109/L, and the time to ANC recovery was defined
as the time from any post-chemotherapy day with ANC
<2 × 109/L to the first day with ANC ≥2 × 109/L. Data were
analyzed and are reported herein for the intent-to-treat (ITT)
population, defined as all patients who were randomized at the
baseline visit (including those with major protocol violations).
P values of FN in the lipegfilgrastim 6 mg and placebo groups
were calculated for patients ≤65 and >65 years of age. P values
and estimates served an informational role only.
Independent ethics committees reviewed and approved the
study protocol, and the study was conducted in accordance with
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the principles of the Declaration of Helsinki and the
International Council for Harmonization Good Clinical
Practice guidelines. Written informed consent was obtained
from all patients before the start of any study-related procedures.
Results
Patient disposition
Overall, 427 patients were screened at 72 centers in 8
European countries (Belarus, Bosnia-Herzegovina, Bulgaria,
Poland, Romania, Russia, Serbia, and Ukraine). Of these, 376
(88.1 %) patients were randomized (1 randomized erroneous-
ly). The ITT population comprised 375 patients (n = 250
lipegfilgrastim; n = 125 placebo). A total of 57 patients
(22.8 %) in the lipegfilgrastim group and 31 patients
(24.8 %) in the placebo group were >65 years old. The safety
population comprised 248 patients who had received
lipegfilgrastim and 125 patients who had received placebo
under double-blind conditions [12].
Patient demographics and baseline disease characteristics, as
summarized in Table 1, were similar between the treatment
groups for patients aged ≤65 years (n = 292) and >65 years
(n = 83). Over 80 % of patients were male in each treatment
group and in each age group. In the overall patient population,
60.8 % of patients in each treatment group had stage IV
NSCLC. In the group of patients >65 years old, 57 patients
(68.7 %) were aged 66 to 70 years, 22 patients (26.5 %) were
aged 71 to 75 years, and 4 patients (4.8%)were aged >75 years.
In the overall ITT population, 250 patients (66.7 %) com-
pleted the study (169 [67.6 %] lipegfilgrastim patients; 81
[32.4 %] placebo patients). When stratified by age, approxi-
mately half of the patients >65 years of age received all 4
chemotherapy cycles (Table 2). Dose delays were more fre-
quent in the placebo group versus the lipegfilgrastim group in
both age groups, but dose reductions and omissions were in-
frequent in both treatment groups, irrespective of age.
Table 1 Patient demographics
and baseline characteristics (ITT
population)
≤65-year population >65-year population
Variable Placebo
n = 95
Lipegfilgrastim
n = 197
Placebo
n = 30
Lipegfilgrastim
n = 53
Age
Mean (SD), year 55.3 (6.7) 55.2 (6.9) 69.4 (2.9) 69.4 (2.8)
Sex, n (%)
Female 15 (15.8) 24 (12.2) 5 (16.7) 6 (11.3)
Male 80 (84.2) 173 (87.8) 25 (83.3) 47 (88.7)
Weight
Mean (SD), kg 70.7 (13.0) 70.2 (13.3) 69.5 (14.7) 64.6 (10.3)
≤60 kg, n (%) 24 (25.3) 49 (24.9) 10 (33.3) 21 (39.6)
>60–≤75 kg, n (%) 42 (44.2) 82 (41.6) 11 (36.7) 24 (45.3)
>75 kg, n (%) 29 (30.5) 66 (33.5) 9 (30.0) 8 (15.1)
NSCLC stage at enrollment, n (%)
Stage IIIB 31 (32.6) 75 (38.1) 18 (60.0) 22 (41.5)
Stage IV 64 (67.4) 122 (61.9) 12 (40.0) 30 (56.6)
Unknown 0 0 0 1 (1.9)
Time since diagnosis, mean (SD),
months
2.8 (6.9) 2.2 (6.1) 5.4 (14.1) 2.8 (6.4)
ECOG performance status, n (%)
0 15 (15.8) 22 (11.2) 4 (13.3) 6 (11.3)
1 75 (78.9) 157 (79.7) 21 (70.0) 37 (69.8)
2 5 (5.3) 18 (9.1) 5 (16.7) 10 (18.9)
Reason for chemotherapy, n (%)
Adjuvant therapy 14 (14.7) 25 (12.7) 7 (23.3) 10 (18.9)
Metastatic disease 81 (85.3) 172 (87.3) 23 (76.7) 43 (81.1)
Lung cancer surgery, n (%)
No 73 (76.8) 170 (86.3) 25 (83.3) 45 (84.9)
Yes 22 (23.2) 27 (13.7) 5 (16.7) 8 (15.1)
ECOG Eastern Cooperative Oncology Group, ITT intent-to-treat,NSCLC non-small cell lung cancer, SD standard
deviation
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Efficacy
Incidence of FN
Among patients aged ≤65 years, there was no difference in the
incidence of FN during cycle 1 in the lipegfilgrastim group
compared with the placebo group (3.0 vs 3.2 %, respectively;
Table 3). Fewer patients aged >65 years receiving
lipegfilgrastim 6 mg (0/53; 0 %) had FN during cycle 1 com-
pared with placebo (4/30; 13.3 %) (Table 3).
Incidence and duration of severe neutropenia
In patients aged ≤65 years, the incidence of severe neutropenia
during cycle 1 was higher in the placebo group than in the
lipegfilgrastim group (56.8 vs 27.6 %, respectively; Table 3).
In patients aged >65 years, there was a smaller difference in
the incidence of severe neutropenia during cycle 1 relative to
that observed in patients aged ≤65 years: 66.7 % with placebo
compared with 49.1 % with lipegfilgrastim (Table 3).
In patients aged ≤65 years, the mean DSN during cycle 1 in
the lipegfilgrastim groupwas 0.6 days comparedwith 2.1 days
in the placebo group (Table 3). Similarly, in patients aged
>65 years, mean DSN during cycle 1 in patients receiving
lipegfilgrastim was shorter (1.0 days) than DSN in patients
receiving placebo (3.0 days) (Table 3).
Time to ANC recovery
In patients aged ≤65 years, the mean time to ANC recovery
during cycle 1 in the lipegfilgrastim group was 6.8 days com-
pared with 13.3 days in the placebo group (Table 3). These
findings were similar to those in patients aged >65 years, in
whom time to ANC recovery during cycle 1 was shorter in
those receiving lipegfilgrastim 6 mg (6.5 days) compared with
those receiving placebo (12.2 days) (Table 3).
Depth of ANC nadir
The mean depth of the ANC nadir during cycle 1 in the
lipegfilgrastim group was higher (1.6 × 109/L) than that in
the placebo group (0.7 × 109/L) in patients aged ≤65 years,
as well as in patients aged >65 years (1.5 × 109/L and
0.5 × 109/L, respectively; Table 3).
Safety
The most common AEs are summarized in Table 4. Overall,
the incidence of AEs was generally similar between
lipegfilgrastim and placebo treatment groups in patients aged
≤65 years and those aged >65 years. In both age groups, the
most common AEs were alopecia, anemia, nausea, and neu-
tropenia. Comparing the elderly and younger lipegfilgrastim
recipients, the percentage of patients experiencing any AE
was generally higher for elderly patients than for younger
patients.
Discussion
A post hoc analysis was conducted in elderly patients with
NSCLC who participated in a phase 3 trial of lipegfilgrastim,
a once-per-cycle glycoPEGylated G-CSF. Patients with a high
individual risk of FN were excluded. For this reason, unlike a
Table 2 Chemotherapy cycles
administered by treatment group ≤65-year population >65-year population
Placebo Lipegfilgrastim Placebo Lipegfilgrastim
n n (%) n n (%) n n (%) n n (%)
Patients completing chemotherapy cycles
1 95 95 (100.0) 197 197 (100.0) 30 30 (100.0) 53 53 (100.0)
2 95 85 (89.5) 197 172 (87.3) 30 24 (80.0) 53 49 (92.5)
3 95 73 (76.8) 197 147 (74.6) 30 19 (63.3) 53 43 (81.1)
4 95 64 (67.4) 197 140 (71.1) 30 17 (56.7) 53 31 (58.5)
Patients with chemotherapy delays
Cycle 2 85 54 (63.5) 172 49 (28.5) 24 17 (70.8) 49 14 (28.6)
Cycle 3 73 45 (61.6) 147 62 (42.2) 19 16 (84.2) 43 18 (41.9)
Cycle 4 64 46 (71.9) 140 61 (43.6) 17 15 (88.2) 31 8 (25.8)
Patients with chemotherapy dose reductions/omissions
Cycle 2 85 0 172 2 (1.2) 24 1 (4.2) 49 1 (2.0)
Cycle 3 73 2 (2.7) 147 1 (0.7) 19 1 (5.3) 43 1 (2.3)
Cycle 4 64 1 (1.6) 140 4 (2.9) 17 1 (5.9) 31 0 (0)
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typical NSCLC population, >75 % of the population was aged
≤65 years, and the overall incidence of FN in the ITT popu-
lation was low [12].
In previously published studies of patients with lung
cancer receiving a similar chemotherapy regimen, in
which use of G-CSF was left to investigator discretion,
a higher incidence of FN was reported (range of 10.4 to
13 %) relative to that observed in our study; however, it is
likely that a less restrictive definition of FN was used in
these studies (thereby leading to higher incidences of FN),
as they were designed to assess the relative efficacy and
safety of two different combination chemotherapy regi-
mens rather than the effectiveness of G-CSF prophylaxis
[13–15]. Moreover, in the present placebo-controlled
study, it was necessary to exclude patients at high risk
for FN due to ethical concerns, which was not the case
in these previously published studies.
In the subset of patients aged >65 years, there was a
difference in the incidence of FN in cycle 1 for patients
receiving lipegfilgrastim (0 %) versus placebo (13.3 %),
which was not observed in the younger subgroup or in the
overall study populations (as published previously [12]).
Although this difference in the incidence of FN was not
statistically significant, it is notable considering the small
number of patients in the elderly subgroup. The differ-
ences in patient demographics and baseline characteristics
between the lipegfilgrastim and placebo groups within the
>65-year population (e.g., 47/53 [89 %] vs 25/30 [83 %]
male and mean time since diagnosis of 2.8 vs 5.4 months)
are unlikely to have caused or contributed to the differ-
ence in neutropenia and febrile neutropenia between these
groups. The 13.3 % incidence of FN in the elderly subset
of patients in the placebo group is in line with earlier
published studies in which the same cisplatin/etoposide
chemotherapy regimen, with or without G-CSF support,
was used at similar dosages to the current study and pa-
tients at high risk for FN were not excluded, suggesting
minimal treatment differences in the elderly versus overall
populations [13–15]. Data for the other efficacy outcomes
reported here were similar between age groups, except
that lipegfilgrastim appeared to exert a greater effect in
reducing the incidence of severe neutropenia in non-
elderly versus elderly patients; however, the ability of
lipegfilgrastim to reduce DSN was evident in both groups,
persisting for no more than 1 day with lipegfilgrastim
versus 2 to 3 days with placebo (consistent with the
Table 4 Most frequent adverse
events (occurring in ≥5 % of
lipegfilgrastim recipients in any
category)
≤65-year population >65-year population
Placebo
n = 95
Lipegfilgrastim
n = 197
Placebo
n = 30
Lipegfilgrastim
n = 53
Adverse event n % n % n % n %
At least 1 event 81 85.3 164 84.1 25 83.3 46 86.8
Non-small cell lung cancer 3 3.2 12 6.2 1 3.3 4 7.5
Anemia 24 25.3 47 24.1 6 20.0 16 30.2
Leukopenia 12 12.6 8 4.1 2 6.7 8 15.1
Neutropenia 36 37.9 37 19.0 8 26.7 14 26.4
Thrombocytopenia 7 7.4 23 11.8 3 10.0 9 17.0
Decreased appetite 10 10.5 14 7.2 2 6.7 9 17.0
Hypokalemia 2 2.1 12 6.2 1 3.3 8 15.1
Hypophosphatemia 1 1.1 7 3.6 1 3.3 5 9.4
Dyspnea 6 6.3 7 3.6 3 10.0 4 7.5
Pulmonary embolism 0 0 2 1.0 2 6.7 1 1.9
Diarrhea 3 3.2 3 1.5 1 3.3 4 7.5
Nausea 19 20.0 46 23.6 8 26.7 13 24.5
Vomiting 11 11.6 17 8.7 4 13.3 11 20.8
Alopecia 35 36.8 78 40.0 7 23.3 23 43.4
Asthenia 14 14.7 18 9.2 9 30.0 10 18.9
Chest pain 6 6.3 12 6.2 2 6.7 2 3.8
Disease progression 4 4.2 14 7.2 1 3.3 2 3.8
Fatigue 5 5.3 10 5.1 1 3.3 6 11.3
Pyrexia 4 4.2 12 6.2 2 6.7 0 0
Weight decreased 2 2.1 7 3.6 0 0 5 9.4
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observed DSN data for the overall population [12]). Data
for DSN are not available for the aforementioned pub-
lished studies of cisplatin/etoposide, but one of the studies
reported FN requiring hospitalization for a median of
6 days with a range of 4 to 24 days [13]. In clinical
practice, the ability to reduce the duration of neutropenic
events would be expected to have a positive effect on both
treatment delivery, in terms of maintaining dose intensity
and scheduled treatment intervals [16], and cost of care.
Of note, in the placebo group, more delays for each cycle
were to be expected and were indeed observed, due to
neutropenia and febrile neutropenia developed during the
previous cycle.
In both age groups, lipegfilgrastim was well tolerated, with
a safety profile similar to that in patients receiving placebo.
The most common AEs were consistent with the known tox-
icity profile of platinum-based chemotherapy. The most nota-
ble differences between lipegfilgrastim and placebo were in
the incidences of hypokalemia and hypophosphatemia, which
were higher among lipegfilgrastim recipients in both age
groups and were more frequent in the elderly versus younger
patients. The percentage of patients experiencing any AE was
generally higher for elderly patients than for younger patients,
which would be expected, considering that elderly patients are
more likely to have comorbidities and be taking more medi-
cations than younger patients.
Limitations of this analysis and the interpretation of the
results stem from the shortcomings that are inherent in post
hoc subgroup analyses, including the reduced sample sizes
when analyzing subgroups based on age or other
characteristics.
Conclusions
In this placebo-controlled study, patients with an individual
high risk of FN as assessed by the investigator were to be
excluded because of ethical considerations. Therefore, it is
not surprising that in the overall study population, the differ-
ence in FN incidence during cycle 1 versus placebo was not
different. In the elderly subpopulation, which has a higher risk
of developing myelosuppression and neutropenia, the FN in-
cidence in cycle 1 in the placebo group (13.3 %) was in the
range expected based on previously published studies [17].
The efficacy of lipegfilgrastim was demonstrated in this sub-
population (FN incidence of 0 %), which is more representa-
tive of the typical at-risk population scheduled to receive pri-
mary G-CSF prophylaxis. In patients with a higher risk, such
as the elderly patients in this study, lipegfilgrastim reduced not
only the duration of severe neutropenia but also the incidence
of FN. However, due to the small number of patients in this
elderly subpopulation, additional prospective studies that
evaluate the clinical benefits of lipegfilgrastim in the elderly
population with NSCLC, as well as benefits such as greater
response, longer progression-free intervals, fewer hospitaliza-
tions, and reduced overall medical costs, are warranted.
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